Protecting people against leprosy: Chemoprophylaxis and immunoprophylaxis

Clinics in Dermatology

Volumn 33, Issue 1, 2015, Pages 19-25

  Richardus, Jan Hendrik ^a   Oskam, Linda ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACEDAPSONE; BCG VACCINE; DAPSONE; LEPROSY VACCINE; MINOCYCLINE; MYCOBACTERIUM VACCINE; OFLOXACIN; RIFAMPICIN; SUBUNIT VACCINE; LEPROSTATIC AGENT;

BACTERIAL TRANSMISSION; BCG VACCINATION; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROL STRATEGY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ELIMINATION; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; LEPROSY; META ANALYSIS (TOPIC); NOTE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; SINGLE DRUG DOSE; FEMALE; HEALTH; IMMUNIZATION; IMMUNOLOGY; INFECTION CONTROL; ISOLATION AND PURIFICATION; MALE; META ANALYSIS; MYCOBACTERIUM LEPRAE; OBSERVATIONAL STUDY; PROCEDURES; RISK ASSESSMENT; TRANSMISSION; WORLD HEALTH ORGANIZATION;

BCG VACCINE; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION; LEPROSTATIC AGENTS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 84922244488     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2014.07.009     Document Type: Note

References (55)

1. World Health Organization Enhanced Global Strategy for Further Reducing the Disease Burden Due to Leprosy (Plan Period: 2011-2015) 2009, World Health Organization, Regional Office for South-East Asia, New Delhi.
2. Global leprosy situation. Wkly Epidemiol Rec 2012, 87:317-328.
3. Richardus J.H., Habbema J.D. The impact of leprosy control on the transmission of M. leprae: is elimination being attained?. Lepr Rev 2007, 78:330-337.
4. Richardus J.H., Meima A., van Marrewijk C.J., et al. Close contacts with leprosy in newly diagnosed leprosy patients in a high and low endemic area: comparison between Bangladesh and Thailand. Int J Lepr Other Mycobact Dis 2005, 73:249-257.
5. Otsyula Y., Ibworo C., Chum H.J. Four years' experience with dapsone as prophylaxis against leprosy. Lepr Rev 1971, 42:98-100.
6. Wardekar R.V. DDS prophylaxis against leprosy. Lepr India 1967, 39:155-159.
7. Noordeen S.K. Chemoprophylaxis in leprosy. Lepr India 1969, 41:247-254.
8. Noordeen S.K., Neelan P.N. Chemoprophylaxis among contacts of non-lepromatous leprosy. Lepr India 1976, 48:635-642.
9. Noordeen S.K. Long term effects of chemoprophylaxis among contacts of lepromatous cases. Results of 8 1/2 years follow-up. Lepr India 1976, 49:504-509.
10. Noordeen S.K., Neelan P.N. Extended studies on chemoprophylaxis against leprosy. Indian J Med Res 1978, 67:515-527.
11. Neelan P.N., Noordeen S.K., Sivaprasad N. Chemoprophylaxis against leprosy with acedapsone. Indian J Med Res 1983, 78:307-313.
12. Neelan P.N., Sirumban P., Sivaprasad N. Limited duration acedapsone prophylaxis in leprosy. Indian J Lepr 1986, 58:251-256.
13. Reveiz L., Buendia J.A., Tellez D. Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. Pan Am J Public Health 2009, 26:341-349.
14. Cartel J.L., Chanteau S., Boutin J.P., et al. Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin. Int J Lepr Other Mycobact Dis 1989, 57:810-816.
15. Cartel J.L., Chanteau S., Moulia-Pelat J.P., et al. Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years. Int J Lepr Other Mycobact Dis 1992, 60:416-420.
16. Nguyen L.N., Cartel J.L., Grosset J.H. Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 2000, 71(71 Suppl.):S33-S35. [discussion S35-36].
17. Blanc L.J. Summary of leprosy chemoprophylaxis programs in the Western Pacific Region. Int J Lepr Other Mycobact Dis 1999, 67:S30-S31.
18. Diletto C., Blanc L., Levy L. Leprosy chemoprophylaxis in Micronesia. Lepr Rev 2000, (71 Suppl.):S21-S23. [discussion S24-25].
19. World Health Organization Epidemiological Review of Leprosy in the Western Pacific Region, 2008-2010 2011, World Health Organization, Western Pacific Region, Manila, Philippines.
20. Proceedings of the Workshop on the Prevention of Leprosy. Pohnpei, Federated States of Micronesia. Int J Lepr Other Mycobact Dis 1999, 67:S1-S82.
21. Smith W.C., Smith C.M. Preventive treatment of leprosy: needs, opportunities, and feasibility. Int J Lepr Other Mycobact Dis 1999, 67:S38-S44.
22. Bakker M.I., Hatta M., Kwenang A., et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg 2005, 72:443-448.
23. Moet F.J., Oskam L., Faber R., et al. A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev 2004, 75:376-388.
24. Moet F.J., Pahan D., Oskam L., et al. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008, 336:761-764.
25. Feenstra S.G., Pahan D., Moet F.J., et al. Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. Lepr Rev 2012, 83:292-304.
26. Schuring R.P., Richardus J.H., Pahan D., et al. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine 2009, 27:7125-7128.
27. Convit J., Sampson C., Zuniga M., et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992, 339:446-450.
28. Karonga Prevention Trial Group Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996, 348:17-24.
29. Gupte M.D., Vallishayee R.S., Anantharaman D.S., et al. Comparative leprosy vaccine trial in south India. Indian J Lepr 1998, 70:369-388.
30. Deo M.G., Bapat C.V., Bhalerao V., et al. Antileprosy potentials of ICRC vaccine. A study in patients and healthy volunteers. Int J Lepr Other Mycobact Dis 1983, 51:540-549.
31. Talwar G.P., Zaheer S.A., Mukherjee R., et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 1990, 8:121-129.
32. Sharma P., Mukherjee R., Talwar G.P., et al. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev 2005, 76:127-143.
33. Truoc L.V., Ly H.M., Thuy N.K., et al. Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam. Vaccine 2001, 19:3451-3458.
34. Setia M.S., Steinmaus C., Ho C.S., et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006, 6:162-170.
35. Zodpey S.P. Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J Dermatol Venereol Leprol 2007, 73:86-93.
36. Merle C.S., Cunha S.S., Rodrigues L.C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010, 9:209-222.
37. Duppre N.C., Camacho L.A., da Cunha S.S., et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008, 102:631-638.
38. Duthie M.S., Gillis T.P., Reed S.G. Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin 2011, 7:1172-1183.
39. Cole S.T., Eiglmeier K., Parkhill J., et al. Massive gene decay in the leprosy bacillus. Nature 2001, 409:1007-1011.
40. Geluk A., van der Ploeg J., Teles R.O., et al. Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection. Clin Vaccine Immunol 2008, 15:522-533.
41. Sampaio L.H., Stefani M.M., Oliveira R.M., et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 2011, 11:26.
42. Geluk A., Bobosha K., van der Ploeg-van Schip J.J., et al. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol 2012, 188:4782-4791.
43. Pannikar V. Enhanced global strategy for further reducing the disease burden due to leprosy: 2011-2015. Lepr Rev 2009, 80:353-354.
44. Smith C., Richardus J.H. Leprosy strategy is about control, not eradication. Lancet 2008, 371:969-970.
45. Rodrigues L.C., Lockwood D.N. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011, 11:464-470.
46. Moet F.J., Pahan D., Schuring R.P., et al. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis 2006, 193:346-353.
47. Moet F.J., Schuring R.P., Pahan D., et al. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl Trop Dis 2008, 2:e198.
48. Fischer E.A., de Vlas S.J., Habbema J.D., et al. The long-term effect of current and new interventions on the new case detection of leprosy: a modeling study. PLoS Negl Trop Dis 2011, 5:e1330.
49. Alam K., Richardus R.A., Geluk A., et al. The combined effect of chemoprophylaxis with rifampicin and immunoprophylaxis with BCG, in the prevention of leprosy in contacts: a randomized controlled trial. Brussels, Belgium: 18th International Leprosy Congress 2013.
50. Oskam L., Slim E., Buhrer-Sekula S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. Lepr Rev 2003, 74:196-205.
51. Moura R.S., Calado K.L., Oliveira M.L., et al. Leprosy serology using PGL-I: a systematic review. Rev Soc Bras Med Trop 2008, 41(Suppl. 2):11-18.
52. Spencer J.S., Duthie M.S., Geluk A., et al. Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz 2012, 107(Suppl. 1):79-89.
53. Dockrell H.M., Geluk A., Brennan P., et al. Report on the sixth meeting of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) consortium held in Beijing, China on 23-25 August 2010. Lepr Rev 2011, 82:80-85.
54. Geluk A. Biomarkers for leprosy: would you prefer T (cells)?. Lepr Rev 2013, 84:1-10.
55. Duthie M.S., Saunderson P., Reed S.G. The potential for vaccination in leprosy elimination: new tools for targeted interventions. Mem Inst Oswaldo Cruz 2012, 107(Suppl. 1):190-196.